Ceruloplasmin replacement therapy

Aceruloplasminemia is a monogenic disease caused by mutations in the ceruloplasmin gene that result in loss of protein ferroxidase activity. Ceruloplasmin plays a role in iron homeostasis, and its activity impairment leads to iron accumulation in liver, pancreas, and brain. Iron deposition promotes diabetes, retinal degeneration, and progressive neurodegeneration.

    Related Conference of Ceruloplasmin replacement therapy

    June 20-21, 2018

    27th European Diabetes Congress

    | Rome, Italy
    July 16-17, 2018 Sydney, Australia

    20th Asia Pacific Diabetes Conference

    July 23-24, 2018

    Global Meeting on Diabetes and Endocrinology

    Kuala Lumpur, Malaysia
    August 20-21, 2018

    28th World Congress on Diabetes, Obesity & Heart

    Tokyo, Japan
    September 03-04, 2018

    2nd International Conference on Thyroid and Pregnancy

    Auckland, New Zealand
    September 3-4, 2018

    11th World Congress on Endocrinology and Metabolic Disorders

    Auckland, New Zealand
    September 13-15, 2018

    26th International Diabetes and Healthcare Conference

    Bucharest, Romania
    Sep 14-15, 2018

    World Congress on Endocrinology

    Prague , Czech Republic
    Sep 14-15, 2018

    Euro Diabetes Congress & Expo

    | Prague, Czech Republic
    September 28-29, 2018

    2nd International Conference on Diabetes and Diabetic Nursing Care

    Montreal, Quebec, Canada
    November 26-27, 2018

    13th European Diabetes and Endocrinology Congress

    Dublin, Ireland

    Ceruloplasmin replacement therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in